Search





Search





Markets
/
Stocks
/
nasdaq-hln
/

Haleon PLC

HLN

Add to Watchlist

9.110USD

-0.185-1.99%

Close 05/08, 16:00（ET）Quotes delayed by 15 min

40.08BMarket Cap

33.07P/E TTM



Haleon PLC

9.110

-0.185-1.99%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Haleon PLC

Currency: USD Updated: 2026-05-08

Key Insights

Haleon PLC's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 65 out of 156 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 10.88.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Haleon PLC's Score

Industry at a Glance

Industry Ranking

65 / 156

Overall Ranking

178 / 4494

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Haleon PLC Highlights

StrengthsRisks

Haleon plc is a consumer healthcare company. The Company’s product portfolio spans six major categories, including oral health, vitamins, minerals and supplements (VMS), pain relief, respiratory health, digestive health and therapeutic skin health and other. The Company’s geographical segments include North America, Europe, Middle East, Africa, and Latin America (EMEA) & LatAm, and Asia Pacific (APAC). Its respiratory health brands offer product solutions for a range of respiratory issues, including cold and flu, nasal congestion, coughs, and allergies. The Company’s oral health brands include Sensodyne, Polident, and Parodontax. Its VMS brands include Centrum, Emergen-C, and Caltrate. Its respiratory brands include Otrivin, Theraflu, Flonase, Contac, and Beechams. Its pain relief brands include Voltaren, Panadol, and Advil. Its digestive health brands include TUMS, ENO, and Benefiber. Its therapeutic skin health brands include Fenistil, Zovirax, and Bactroban.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 8.14B.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 41.40%.

Undervalued

The company’s latest PE is 33.07, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 568.91M shares, increasing 1.15% quarter-over-quarter.

Held by Mairs and Power

Star Investor Mairs and Power holds 28.72K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.10.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

10.878

Target Price

+16.97%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-08

The current financial score of Haleon PLC is 8.65, ranking 33 out of 156 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

8.65

Change



Financials

6.05

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.21

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Haleon PLC's Company Valuation

Currency: USD Updated: 2026-05-08

The current valuation score of Haleon PLC is 4.63, ranking 153 out of 156 in the Pharmaceuticals industry. Its current P/E ratio is 33.07, which is 244.77% below the recent high of 114.00 and 0.00% above the recent low of 33.07.

Score

Industry at a Glance

Previous score

4.63

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 65/156

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-08

The current earnings forecast score of Haleon PLC is 8.00, ranking 58 out of 156 in the Pharmaceuticals industry. The average price target is 11.50, with a high of 13.44 and a low of 5.88.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

10.878

Target Price

+16.97%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

Haleon PLC

HLN

Amgen Inc

AMGN

Biogen Inc

BIIB

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

Vertex Pharmaceuticals Inc

VRTX

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-08

The current price momentum score of Haleon PLC is 6.50, ranking 115 out of 156 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 9.62 and the support level at 8.82, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.95

Change

-0.45

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.015

Sell

RSI(14)

34.133

Neutral

STOCH(KDJ)(9,3,3)

23.834

Neutral

ATR(14)

0.183

High Vlolatility

CCI(14)

-114.673

Sell

Williams %R

90.476

Oversold

TRIX(12,20)

-0.307

Sell

StochRSI(14)

16.963

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

9.210

Sell

MA10

9.293

Sell

MA20

9.457

Sell

MA50

9.868

Sell

MA100

10.131

Sell

MA200

9.797

Sell

Institutional Confidence

Currency: USD Updated: 2026-05-08

The current institutional shareholding score of Haleon PLC is 3.00, ranking 94 out of 156 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 12.80%, representing a quarter-over-quarter increase of 4.21%. The largest institutional shareholder is Van Duyn Dodge & E. Morris Cox, holding a total of 151.76M shares, representing 3.41% of shares outstanding, with 9.27% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Dodge & Cox

Star Investors

151.76M

-1.70%

Fidelity Management & Research Company LLC

92.14M

+3.39%

ClearBridge Investments, LLC

31.42M

-5.77%

Harding Loevner LP

16.62M

-7.22%

Norges Bank Investment Management (NBIM)

16.18M

+5781.82%

Fidelity Institutional Asset Management

12.09M

+6.16%

Sculptor Capital Management, Inc

10.45M

+5.08%

Ostrum Asset Management

10.00M

+429.78%

Morgan Stanley Smith Barney LLC

9.23M

+19.85%

Parametric Portfolio Associates LLC

8.24M

+9.01%

Risk Assessment

Currency: USD Updated: 2026-05-08

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Haleon PLC is 9.95, ranking 1 out of 156 in the Pharmaceuticals industry. The company's beta value is 0.13. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.